eicosapentaenoic acid ethyl ester and Apoplexy

eicosapentaenoic acid ethyl ester has been researched along with Apoplexy in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (22.22)	24.3611
2020's	7 (77.78)	2.80

Authors

Authors	Studies
Gaba, P	2
Bhatt, DL	5
Giugliano, RP	4
Steg, PG	5
Miller, M	5
Brinton, EA	5
Jacobson, TA	5
Ketchum, SB	5
Juliano, RA	5
Jiao, L	5
Doyle, RT	5
Granowitz, C	5
Tardif, JC	5
Ballantyne, CM	5
Pinto, DS	1
Budoff, MJ	3
Gibson, CM	4
Peterson, BE	1
Pinto, D	1
Verma, S	1
Martens, FMAC	1
Olshansky, B	2
Kowey, PR	1
Reiffel, JA	1
Chung, MK	2
Dron, JS	1
Hegele, RA	1
Wong, ND	1
Fan, W	1
Philip, S	1
Toth, PP	1
Myran, L	1
Nguyen, TN	1
Lee, M	1
Ovbiagele, B	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)[NCT01492361]			Phase 3	8,179 participants (Actual)	Interventional	2011-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Composite of CV Death or Nonfatal MI (Including Silent MI).

Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	392
Placebo	507

Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.

The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	705
Placebo	901

Composite of CV Death, Nonfatal MI (Including Silent MI), or Nonfatal Stroke.

The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	459
Placebo	606

CV Death.

Number of patients with an occurrence of CV death during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	174
Placebo	213

Fatal or Nonfatal MI (Including Silent MI).

Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	250
Placebo	355

Fatal or Nonfatal Stroke.

Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	98
Placebo	134

Non-elective Coronary Revascularization Represented as the Composite of Emergent or Urgent Classifications.

Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	216
Placebo	321

Total Mortality, Nonfatal MI (Including Silent MI), or Nonfatal Stroke.

Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	549
Placebo	690

Total Mortality.

Number of patients with an occurrence of death from any cause during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	274
Placebo	310

Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.

Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	108
Placebo	157

Trials

5 trials available for eicosapentaenoic acid ethyl ester and Apoplexy

Article	Year
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 10-12, Volume: 78, Issue:15 Topics: Aged; Angina, Unstable; Eicosapentaenoic Acid; Endpoint Determination; Female; Humans; Hypertriglyce	2021
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Journal of the American Heart Association, 2022, 03-15, Volume: 11, Issue:6 Topics: Double-Blind Method; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;	2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Journal of the American College of Cardiology, 2022, 05-03, Volume: 79, Issue:17 Topics: Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia;	2022
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. Journal of the American Heart Association, 2023, 03-07, Volume: 12, Issue:5 Topics: Atrial Fibrillation; Eicosapentaenoic Acid; Humans; Risk Factors; Stroke; Treatment Outcome	2023
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation, 2020, 02-04, Volume: 141, Issue:5 Topics: Aged; Cholesterol, LDL; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglu	2020

Other Studies

4 other studies available for eicosapentaenoic acid ethyl ester and Apoplexy

Article	Year
Ischemic Event Reduction and Triglycerides. Journal of the American College of Cardiology, 2019, 10-08, Volume: 74, Issue:14 Topics: Brain Ischemia; Eicosapentaenoic Acid; Humans; Stroke; Triglycerides	2019
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]). The American journal of cardiology, 2020, 11-01, Volume: 134 Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus; Eicosapentaenoic Acid; Eligibili	2020
Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke. American family physician, 2021, 01-15, Volume: 103, Issue:2 Topics: Eicosapentaenoic Acid; Humans; Hypercholesterolemia; Lipid Regulating Agents; Myocardial Infarction;	2021
Effect of icosapent ethyl on stroke risk: Different strokes for different folks? Journal of the neurological sciences, 2019, Jun-15, Volume: 401 Topics: Asian People; Cardiovascular Diseases; Eicosapentaenoic Acid; Ethnicity; Humans; Hypertriglyceridemi	2019